(NASDAQ: APRE) Aprea Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 5.1%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.23%.
Aprea Therapeutics's earnings in 2025 is -$13,850,097.On average, 1 Wall Street analyst forecast APRE's earnings for 2025 to be -$4,135,935, with the lowest APRE earnings forecast at -$4,135,935, and the highest APRE earnings forecast at -$4,135,935. On average, 1 Wall Street analyst forecast APRE's earnings for 2026 to be -$3,203,894, with the lowest APRE earnings forecast at -$3,203,894, and the highest APRE earnings forecast at -$3,203,894.
In 2027, APRE is forecast to generate $1,922,336 in earnings, with the lowest earnings forecast at $1,922,336 and the highest earnings forecast at $1,922,336.